Get the Stockscreener App
1.74
1.16%
0.02
After Hours:
1.72
-0.02
-1.15%
Nkarta Inc stock is traded at $1.74, with a volume of 591.17K.
It is up +1.16% in the last 24 hours and down -0.57% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$1.72
Open:
$1.74
24h Volume:
591.17K
Relative Volume:
0.46
Market Cap:
$123.47M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.725
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-9.84%
1M Performance:
-0.57%
6M Performance:
-31.23%
1Y Performance:
-74.49%
1-Day Range:
$1.70
$1.755
1-Week Range:
$1.675
$2.085
52-Week Range:
$1.31
$8.23
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.74 | 136.95M | 0 | -117.50M | -114.31M | -2.40 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Needham & Company LLC Lowers Nkarta (NASDAQ:NKTX) Price Target to $10.00 - Defense World
Nkarta (NASDAQ:NKTX) Earns “Market Perform” Rating from William Blair - Defense World
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Dimensional Fund Advisors LP Has $1.42 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Stifel Financial Corp - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. Reports Q1 2025 Financial Results - TipRanks
Nkarta stock rating downgraded at William Blair to Market Perform By Investing.com - Investing.com South Africa
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space - Benzinga
Nkarta (NKTX) Experiences Downgrade Amid Clinical Protocol Changes | NKTX Stock News - GuruFocus
NKTX's Strategic Moves to Reach Clinical Milestones and Extend C - GuruFocus
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX S - GuruFocus
Needham Maintains 'Buy' Rating on Nkarta (NKTX) as Price Target Adjusts | NKTX Stock News - GuruFocus
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
NKTX: William Blair Downgrades Nkarta to Market Perform | NKTX Stock News - GuruFocus
William Blair Downgrades Nkarta to Market Perform From Outperform - marketscreener.com
Nkarta stock rating downgraded at William Blair to Market Perform - Investing.com
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta's $351.9M War Chest Funds Operations Until 2029 as Clinical Trials Expand in Autoimmune Diseases - Stock Titan
Nkarta, Inc. (NASDAQ:NKTX) Shares Acquired by Wells Fargo & Company MN - Defense World
Barclays PLC Has $674,000 Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Financial Snapshot: Analyzing Nkarta Inc (NKTX)’s Key Ratio Metrics - DWinneX
11,997 Shares in Nkarta, Inc. (NASDAQ:NKTX) Purchased by Invesco Ltd. - Defense World
Uncovering the Potential of Nkarta Inc (NKTX) Stock - investchronicle.com
A stock that deserves closer examination: Nkarta Inc (NKTX) - uspostnews.com
Nkarta Inc (NKTX) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Daily Market Movement: Nkarta Inc (NKTX) Sees a -4.74 Decrease, Closing at 2.01 - DWinneX
Geode Capital Management LLC Has $2.94 Million Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Nkarta Inc’s Market Journey: Closing Weak at 1.56, Down -4.29 - DWinneX
A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com
Technical analysis of Nkarta Inc (NKTX) stock chart patterns - uspostnews.com
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 2.18 - DWinneX
Insider Sale Alert: Nkarta Inc [NKTX] – Is it Time to sell? - knoxdaily.com
A Tale of Resilience: Nkarta Inc Amid Stock Market Turbulence - investchronicle.com
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World
JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta (NKTX) Upgraded to Buy: Here's Why - NewsBreak: Local News & Alerts
Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com
American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World
CAR NK Expert With 25-Year Track Record Strengthens Senti Bio's Scientific Leadership - Stock Titan
Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
| Hager Alicia J. | Chief Legal Officer |
Jul 16 '24 |
Sale |
8.00 |
3,396 |
27,168 |
103,819 |
| Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
| HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
| Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
| Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
| Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):